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Abstract
Change in gene expression associated with pancreatic cancer could be attributed to the variation in histone
posttranslational modifications leading to subsequent remodeling of the chromatin template during transcription.
However, the interconnected network of molecules involved in regulating such processes remains elusive. hPaf1/PD2, a
subunit of the human PAF-complex, involved in the regulation of transcriptional elongation has oncogenic potential. Our
study explores the possibility that regulation of histone methylation by hPaf1 can contribute towards alteration in gene
expression by nucleosomal rearrangement. Here, we show that knockdown of hPaf1/PD2 leads to decreased di- and tri-
methylation at histone H3 lysine 4 residues in pancreatic cancer cells. Interestingly, hPaf1/PD2 colocalizes with MLL1 (Mixed
Lineage Leukemia 1), a histone methyltransferase that methylates H3K4 residues. Also, a reduction in hPaf1 level resulted in
reduced MLL1 expression and a corresponding decrease in the level of CHD1 (Chromohelicase DNA-binding protein 1), an
ATPase dependent chromatin remodeling enzyme that specifically binds to H3K4 di and trimethyl marks. hPaf1/PD2 was
also found to interact and colocalize with CHD1 in both cytoplasmic and nuclear extracts of pancreatic cancer cells. Further,
reduced level of CHD1 localization in the nucleus in hPaf1/PD2 Knockdown cells could be rescued by ectopic expression of
hPaf1/PD2. Micrococcal nuclease digestion showed an altered chromatin structure in hPaf1/PD2-KD cells. Overall, our results
suggest that hPaf1/PD2 in association with MLL1 regulates methylation of H3K4 residues, as well as interacts and regulates
nuclear shuttling of chromatin remodeling protein CHD1, facilitating its function in pancreatic cancer cells.
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Introduction
Post-translational modifications of basic histone proteins, such
as phosphorylation, methylation, acetylation, ubiquitylation or
sumoylation, play a major role in regulating gene expression. One
way by which such histone modifications function is by
recruitment of downstream effector proteins which perform
specific independent functions on the chromatin template. These
include the chromatin remodeling proteins which ‘‘read’’ the
modified histone marks and use ATP energy to alter the position of
nucleosomes on the DNA. As a result, the chromatin template is
either blocked or made accessible to the transcription machinery,
hence regulating downstream gene expression. Histone methyla-
tion, specifically the histone H3 lysine 4 residue mono-, di- and
trimethylation, is mostly associated with 59 regions of actively
transcribed genes [1]. However, a recent study shows that in
regions of DNA damage, ING proteins recruit HDAC complexes
to silence transcription of cell proliferation genes through
recognition of trimethylated H3K4 residues by their PHD
domains [2]. This is the first report linking K4 trimethylation to
actively repressed genes as well.
In mammals, the methylation at the H3K4 residue is carried out
by the histone methyltransferase MLL1, a SET domain containing
protein which remains in a complex with other subunit proteins
WDR5, RbBP5 and ASH2 [3]. The yeast homologue of MLL1,
Set1, is a part of a macromolecular complex called COMPASS
(complex of proteins associated with Set1) that interacts with yeast
PAF complex for histone methylation [4]. It has been postulated
that some conserved genes, from Drosophila to humans, bear this
methylation mark exclusively and the expression of these genes is
regulated by Pol II general elongation factors [1]. The H3K4
histone methylation marks can be further recognized by specific
proteins, resulting in recruitment and subsequent enzymatic or
physiological activity at the site of recruitment. CHD1 (Chromo-
domain Helicase DNA binding protein 1) is a protein belonging to
the family of ATPase dependent chromatin remodeling factors that
specifically associate with dimethylated and trimethylated H3K4
[5,6]. The human CHD1 binds to the methylated histone H3K4
residue through both of its tandem chromodomains, whereas the
yeast Chd1 fails to bind methylated H3K4 residues [7].
Cancer development and progression is attributed to dysregu-
lated gene expression which might often correlate to either faulty
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epigenetic activation or silencing of genes [8]. Altered histone
modification patterns cause mistargeting of chromatin remodeling
enzymes that might lead to uncontrolled gene expression and
hence cause normal cells to be transformed into cancer cells.
Pancreatic cancer is the fourth leading cause of cancer with a very
poor prognosis and five year survival rate of less than 5%. Like
other forms of malignancy, pancreatic cancer is also correlated to
epigenetic alterations such as DNA methylation and histone
modifications, leading to an altered gene expression [9].
PD2 is the human homologue of the yeast RNA polymerase II-
associated factor 1 (yPaf1) which constitutes the core subunit of the
human RNA Polymerase II associated factor (hPAF) complex.
Similar to its yeast counterpart, the hPAF complex is comprised of
four other subunits, namely hLeo1, hCtr9, hSki8 and parafibro-
min [10–12]. The major functions of the hPAF complex involves
transcriptional elongation, mRNA processing and maturation,
similar to that of the yeast PAF complex [12]. Chromatin
modification and remodeling are also some of the characteristics of
transcription factors. Evidently, a host of histone modifications
have been linked to the PAF complex and transcription elongation
as well [4,13]. Both the yeast and the human PAF complex are
found to be necessary for Rad6/Bre1-dependent ubiquitylation of
histone H2B [14]. The monoubiquitylation of H2B by hPAF
removes the nucleosomal barrier, which is a prerequisite for
efficient transcription elongation on chromatin by RNA Pol II
[14]. The presence of ubiquitylated H2B further triggers H3K4 di
and tri-methylation. In yeast, the Paf1C function in H3K4-Me3
formation is conferred by the Rtf1 subunit by recruiting the SET1
histone methyltransferase complex [15], which is homologous to
the human MLL complex [16]. Yeast studies also show that the
Paf1 complex is required for recruitment of the COMPASS
methyltransferase complex to RNA polymerase II through subunit
interaction. In human cells, hCdc73 appears to be required for full
levels of H3K36-Me3 [17], but not H3K4-Me3, whereas in yeast
Cdc73 is required for both modifications [18]. Therefore, the role
of PAF complex in transcription elongation has been closely
correlated to histone modifications.
Besides its role in transcription regulation, the human PAF
complex subunits have also been linked to a malignant phenotype.
Parafibromin (hCdc73) is found to be mutated in parathyroid
tumors and amplified in liver and breast carcinoma. Leo1, present
at the 15q21 locus, is amplified in colorectal cancer and malignant
fibrous histiocytoma of the bone, whereas the Ctr9 gene locus is
found to be deleted in pancreatic cancer. The hPaf1 subunit of the
human PAF complex, also known as PD2, is amplified and
overexpressed in pancreatic cancer and its possible role in
tumorigenesis is indicated by the induction of a transformed
phenotype on overexpression [19]. In this study, we identify a role of
hPaf1/PD2 in regulating histone methylation at the H3K4 residue
in pancreatic cancer cells by interaction with histone methyltrans-
ferase MLL1. It was also found to regulate the expression of the
chromatin remodeling factor, CHD1 that specifically binds to di
and trimethylated H3K4 and facilitate its nuclear import, probably
through direct interactions. Further, micrococcal nuclease digestion
assays show that knockdown of PD2 leads to altered nucleosomal
positioning in pancreatic cancer cells.
Materials and Methods
Cell culture
Human pancreatic cancer cell lines Panc1 and MiaPaca were
obtained from ATCC. The cells were culture in DMEM media
(Sigma) supplemented with 10% fetal bovine serum (Sigma) and
1% pencillin-streptamycin solution (Sigma). Culture medium was
changed every 2 days and cells were subcultured by trypsin-EDTA
treatment.
RNA Isolation and QRT-PCR
Total cellular RNA was extracted from Panc1 cells using the
RNAeasy kit (Qiagen) and processed for reverse transcription. The
initial PCR activation step was at 94uC for four minutes, followed
by the denaturation step at 94uC for one minute, primer-annealing
step at 58uC for 30 seconds, extension step at 72uC for one
minute, and the final extension step at 72uC for ten minutes. PCR
reaction products were then separated by electrophoresis using a
2% agarose gel. Gels were stained using 0.5 mg/ml of ethidium
bromide, illuminated with UV light. Total cell RNA was reverse-
transcribed and assayed by quantitative real-time PCR using
SYBR Green incorporation. The expression of all genes was
normalized to that of the internal control b-actin and expressed
relative to the indicated reference sample (average 6 S.D. of
triplicate reactions). The expressions of lineage specific genes were
compared between the scrambled and PD2 knockdown Panc1
cells by the two-tailed Student’s t-test. A p-value of ,0.05 was
considered statistically significant.
RNA Interference
The region of Paf1/PD2 was targeted with specific siRNA
(sequence 59- AACAGGUUCGUCCAGUACAAA-3)9. Synthetic
sense and antisense oligonucleotides (Dharmacon, Lafayette, CO)
were annealed in 100 mM potassium acetate, 30 mM HEPES-
KOH (pH 7.4), and 2 mM magnesium acetate for one minute at
90uC and one hour at 37uC, and frozen. Oligonucleotides were
transfected into cells with TransIT-TKO (Mirus, Madison, WI) in
accordance with the supplier’s recommendations.
Immunoblot Assay
Panc1 and MiaPaCa cell lines were processed for protein
extraction and Western blotting using standard procedures.
Briefly, the cells were washed twice in PBS and lysed in RIPA
buffer (100 mM Tris, 5 mM EDTA, 5% NP40;pH 8.0) containing
protease inhibitors (1 mM phenyl-methyl sulphonyl fluoride,
1 mg/ml aprotinin, 1 mg/ml leupeptin) and kept at 4uC and
supernatants were collected. Twenty mg of protein lysates was
resolved in 10% SDS-PAGE. Resolved proteins were transferred
on to the PVDF membrane. After quick washing in PBST
(Phosphate buffered saline and 0.1% Tween 20), the membranes
were blocked in 5% nonfat dry milk in PBS for at least 2 h and
then incubated with primary antibodies (anti-Paf1/PD2, anti-
Leo1, anti-Cdc, anti-Ski8, anti- Oct3/4, anti-SOX2, anti-b-actin)
(diluted in 3% BSA in PBS) overnight at 4uC. The membrane was
then washed (3610 min) in PBST at room temperature and
probed with 1:2000 diluted horseradish peroxidase-conjugated
anti-mouse or anti-rabbit secondary antibodies for 1 h at room
temperature and washed 5610 min with PBST. The signal was
detected with an ECL chemiluminescence kit (Amersham
Bioscience, UK). All the western blots were quantified using the
ChemiImager 4400 software. The graphs generated show error
bars representing the standard errors as calculated from three
independent experimental replicates. The difference in each
protein level between scrambled and PD2 knockdown cells are
analyzed by Students t-test with a p-value of less than 0.05 being
considered statistically significant.
Confocal Microscopy
Cells were plated onto sterile round cover slips (CIR 18-1 Fisher
brand 12-545-10) and grown in 12-well plates for 24 hrs. Cells
hPaf1 in Chromatin Remodeling of Pancreatic Cancer
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26926
were fixed in ice cold methanol (pre-chilled to 220uC) and
permeabilized with 0.1% Triton X-100 in PBS. Then, the cells
were washed in PBS and blocked using 10% goat serum for
30 mins. After blocking, it was incubated with primary (PD2
mouse monoclonal, CHD1 rabbit polyclonal) antibodies for one
hour and fluorescent tagged secondary antibodies (FITC goat anti-
mouse, Texas-Red goat anti-rabbit) for 30 mins at room
temperature. Antibodies were diluted in 5% goat serum. Finally,
following secondary antibody incubation, the cells were washed
with TBST three times and cover slips were mounted with
vectashield containing DAPI (VECTOR).
Isolation of cytoplasmic and nuclear extract
The protocol for cytoplasmic and nuclear extract preparation
was adapted from previously published procedures. Cells were
rinsed twice in ice cold PBS and incubated on ice for 30 minutes
in hypotonic cytoplasmic extraction buffer (10 mM Hepes,
pH 7.4, 10 mM KCl, 0.2% NP-40, 0.1 mM EDTA, 10% glycerol,
1.5 mM MgCl2, 1 mM DTT, 1 mM PMSF, 5 mM Na3VO4,
5 mM NaF), supplemented with complete protease inhibitor
cocktail [Roche]. Cell disruption was accomplished by several
passages through a 25G needle. Nuclei were collected by
centrifugation at 16,000 g, and the supernatant further centrifuged
at 16,000 g to yield the final cytoplasmic extract. Nuclear pellets
were washed twice with ice cold PBS followed by incubation in
hypertonic nuclear extraction buffer (20 mM Hepes, [pH 7.6],
420 mM NaCl, 1 mM EDTA, 20% glycerol, 1.5 mM MgCl2,
1 mM DTT, 1 mM PMSF, 5 mM Na3VO4, 5 mM NaF),
supplemented with complete protease inhibitor cocktail [Roche].
The solution was further sonicated at 60% amplitude twice for
10 seconds each. Insoluble materials were precipitated by
centrifugation. The supernatant was collected and used as nuclear
extract.
Immunoprecipitation Analysis
Equal amounts of Protein A+ G-Sepharose beads (Oncogene
Research, Boston, MA) were incubated overnight with anti-PD2
(rabbit polyclonal) and anti-CHD1 (rabbit polyclonal) antibodies
in a 1 ml total volume. It was then washed twice to remove the
unbound antibody and 1.5 mg of protein lysate was added to the
bead-antibody mix and incubated on a rotating platform for 5 h at
4uC. Following the incubation period, the mixtures were washed
five times with lysis buffer. The immunoprecipitates or total cell
lysates were electrophoretically resolved on SDS-PAGE (10%).
Resolved proteins were transferred on to the PVDF membrane.
After quick washing in PBST (Phosphate buffered saline and 0.1%
Tween 20), the membranes were blocked in 5% nonfat dry milk in
PBS for at least 2 h and then incubated with primary antibodies
(anti- Paf1/PD2, Oct3/4 and RNA Pol II). The immunoblots
were washed five times (5610 min), incubated 1 h with horserad-
ish peroxidase-conjugated secondary antibodies, washed five times
(5610 min), reacted with enhanced chemiluminescence ECL
reagent (Amarsham Bioscience, Buckinghamshire, UK), and
exposed to X-ray film to detect the signal.
Micrococcal Nuclease Assay
The micrococcal nuclease assay was carried out as mentioned
earlier [20] with some modifications. Fifty6106 cells were pelleted
at 2000 RPM at 4uC for 10 minutes, followed by washing with
10 ml of ice-cold PBS and again pelleted as before. The cells were
then resuspended in 5 ml of ice-cold NP-40 lysis buffer (10 mM
tris-HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl2, 0.5% Nonidet P-
40, 0.15 mM spermine and 0.5 mM spermidine), incubated for
5 mins on ice and the nuclei were repelleted. The nuclei was
washed with 2.5 ml of MNase digestion buffer (10 mM Tris-HCl,
15 mM NaCl, 60 mM KCl, 0.15 mM spermine and 0.5 mM
spermidine) and after centrifugation further resuspended in 1 ml
of MNase digestion buffer containing 2 mM CaCl2. From the
resuspended solutions, 100 ml aliquots were taken and incubated
with increasing amounts of the Micrococcal Nuclease enzyme (0,
80 and 100 units) for 5 and 10 minutes. The reaction was stopped
by adding 80 ml of MNase digestion buffer, 20 ml of MNase stop
buffer (100 mM EDTA, 10 mM EGTA), 3 ml of Proteinase K
(25 mg/ml) and 10 ml of 20% SDS and incubated overnight at
37uC. The following day, the samples are extracted with 200 ml of
phenol-chloroform solution. The samples were spun and an
aqueous layer was collected. Two ml of RNAse A (10 mg/ml) was
added to the solution and incubated at 37uC for 2 hours and again
phenol-chloroform extraction was performed. Further, the DNA
was precipitated by adding 100% ethanol and after centrifugation,
the DNA pellet was resuspended in DNA hydration buffer or
water. Five mg of the isolated DNA was resolved in a 1.4% agarose
gel and visualized by ethidium bromide staining. ImagJ software
was used for densitometry analysis of the DNA banding patterns in
control, Scrambled and PD2 KD PC cells.
Results
hPaf1/PD2 affects other PAF complex subunits in PC cells
The human PAF complex consists of five subunits, similar to its
yeast counterpart, namely hPaf1, parafibromin (hCdc73), hCtr9,
hLeo1 and the hSki8 subunit, which is also a part of the human
SKI complex. Earlier reports have shown that the subunits of the
human PAF complex demonstrate coordinated expression where
knockdown of either hCtr9 or the hSki8 subunit led to a reduction
in levels of the other subunits such as hPaf1 and hLeo1 [12]. This
is consistent with the observation in yeast, where deletion of
individual subunits leads to various degrees of reduction in the
protein levels of other subunits [21]. Interestingly, recent data
from our lab has shown that, the PAF complex subunits function
independently in mouse embryonic stem cells, such that
knockdown of the Paf1 subunit does not affect the level of the
other subunits [22]. To analyze the functional importance of
hPaf1, the major subunit of the hPAF complex, in pancreatic
cancer, we transiently knocked down hPaf1/PD2 in the pancreatic
cancer cell lines Panc1 and MiaPaCa. In corroboration with
earlier reports, we found that hPaf1/PD2 has a coordinated
expression with the other subunits of the hPAF complex. Western
Blot analysis of hCdc73 (parafibromin), hLeo1, hSki8 and hCtr9
proteins and subsequent quantification showed decreased expres-
sion levels of the hLeo1,hCdc73 and hCtr9 subunit in the hPaf1
knockdown Panc1 and MiaPaCa cells compared to the scrambled
siRNA treated cells (Fig. 1) although not statistically significant.
(p.0.05) However there was no observable change in the protein
level of hSki8 subunit upon downregulation of the hPaf1 subunit.
We further confirmed the results by using a different pool of
siRNAs (Santa Cruz, CA) directed against PD2 and observed
similar effects (Fig. S3). These results show that knockdown of one
subunit of the hPAF complex affects the expression of the other
members in order to maintain a general stoichiometric ratio of the
complex in pancreatic cancer cells. Further, it also emphasizes the
differential expression and function of individual subunits of the
PAF complex in different carcinomas.
hPaf1/PD2 influences histone methylation in PC cells
The yeast PAF complex has a well established role in histone
modifications such as ubiquitylation and methylation [4,23–25]. It
is known to mediate the interaction among the Rad6-Bre1
hPaf1 in Chromatin Remodeling of Pancreatic Cancer
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complex, COMPASS histone methyltransferase, and RNA Pol II,
leading to the ubiquitination of histone H2B at lysine 123 residue,
which is a subsequent trigger for methylation at the lysine 4
residue of Histone H3 [24]. An earlier study has shown that RNAi
against hCtr9 or hSki8 led to a reduction in the cellular level of
histone H3K4 mono and trimethylation marks but not dimethyla-
Figure 1. Expression of human PAF complex molecules in scrambled and PD2 RNAi Panc1 and MiaPaCa cells. Panc1 and MiaPaCa
pancreatic cancer cells were transfected with scrambled and PD2 specific siRNA oligos and protein lysates were collected at 72 hours post-
transfection. Western blot analysis of the cell lysates using corresponding antibodies showed the expression of hPaf1/PD2 and other PAF complex
molecules (parafibromin, hLeo1, hSki8 and hCtr9) in scrambled and Paf1/PD2 RNAi treated Panc1 and MiaPaCa cells. The expression of histone 3
Lysine 4 residue mono, di and tri-methylation marks showed a reduced level in hPaf1/PD2 knockdown Panc1 and MiaPaCa cells compared to
scrambled RNAi treated cells. The total Histone H3 level is the same in both scrambled and PD2 knocked down cells. b-actin served as a loading
control. Quantification of the western blots for each cell line is provided below the immunoblot figures with corresponding error bars. * represents
significant change (p,0.05) in protein level between scrambled and PD2 knockdown cells.
doi:10.1371/journal.pone.0026926.g001
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tion marks in Hela cells, indicating a possible role of the human
PAF complex in histone methylation as well [12]. We found that
transient knockdown of hPaf1/PD2 using specific RNAi in
pancreatic cancer cells affects histone methylation at the H3K4
residue (Fig. 1). Western Blot analysis of mono, di and
trimethylation marks at the histone H3 lysine4 residue showed a
significant reduction (*p,0.05) in di- and trimethylated H3K4
levels in PD2 knockdown Panc1 and MiaPaCa cells as compared
to scrambled RNAi treated cells. However, there was not much
variation in the H3K4 monomethylation levels due to PD2
depletion in pancreatic cancer cells. The experiments were
repeated with a different pool of PD2 specific siRNAs in both
cell lines (Fig. S3). We again observed downregulation of histone
di- and trimethylation marks as before with little or no variation in
histone monomethyl levels.
hPaf1/PD2 regulates histone methyltransferase MLL1
protein level
Based on the observation that hPaf1/PD2 regulates histone di
and tri-methylation at the H3K4 residue, we wanted to investigate
the effect of hPaf1 knockdown on histone methyltransferases. The
MLL1 protein belonging to the SET1 family of lysine methyl-
transferases is known to specifically regulate di-and trimethylation
at histone H3 lysine 4 residues. Therefore, we analyzed the effect
of hPaf1/PD2 knockdown on MLL1 protein expression using two
different sets of PD2 siRNAs in Panc1 and MiaPaCa pancreatic
cancer cell lines. Western blot analysis revealed that a decrease in
hPaf1/PD2 level in pancreatic cancer cells leads to a significant
decrease (*p,0.05) in MLL1 protein level (Fig. 2A, S3). The
graphs provided below the immunoblotting results represent
quantification of the western blots for each cell line. We further
looked at PD2 and MLL1 proteins in pancreatic cancer cells by
confocal microscopy and found that the two proteins colocalize in
the nucleus, thereby suggesting a possible interaction between
them (Fig. 2B). However, the amount of colocalization of the two
proteins was relatively low, which indicates a possibly weak and/or
transient interaction. These results were in corroboration with
earlier studies which showed that both the yeast and human PAF
complexes interact with the corresponding homologue of MLL or
Set1 protein [4,26,27]. Therefore, our results suggest that hPaf1/
PD2 regulates, and possibly interacts with MLL1, to control
H3K4 methylation in pancreatic cancer cells.
Knockdown of hPaf1/PD2 decreases CHD1 level in
pancreatic cancer cells
The regulation of histone methylation by the hPaf1/PD2
subunit of the hPAF complex raises the possibility that it might
affect various other proteins, such as chromatin remodeling
factors, which interact with modified histones at sites of
transcription. A putative chromatin remodeling complex, CHD-
1 (Chromodomain Helicase DNA-binding protein 1), was
identified adventitiously as a mammalian DNA-binding protein,
which contains three signature sequence motifs: the 52-amino acid
chromodomain found in the heterochromatin protein HP-1 and
the homeotic repressor Polycomb, the SNF2/SWI2 ATPase
domain, and motifs characteristic of minor-groove DNA binding
proteins [28,29]. Interestingly, the CHD1 chromatin remodeling
protein is known to specifically bind to the methylated lysine 4
residue of histone H3, which is a hallmark of active transcription.
It is postulated that the human CHD1 chromodomains are
responsible for recognition and interaction with the histone
methylation marks [30]. Given that hPaf1/PD2 regulated histone
methylation at the H3K4 residue, we investigated CHD1
regulation by hPaf1 by transient knockdown of hPaf1/PD2 in
pancreatic cancer cells and analyzed the variation in levels of the
CHD1 protein. Western blot analysis along with corresponding
quantification data provided below the immunoblotting figures
(Fig. 3A) shows that knockdown of hPaf1/PD2 in pancreatic
cancer cells leads to a decrease in the level of CHD1 compared to
the scrambled control cells. Downregulation of CHD1 as an effect
of PD2 knockdown was further confirmed in the same cell lines
using a different siRNA pool against PD2 (Fig. S3). In order to
validate this effect, immunofluorescence microscopy was used.
Consistent with the biochemical data, the immunofluorescence
analysis showed that the CHD1 level is decreased in hPaf1/PD2
knockdown Panc1 and MiaPaCa cells compared to the scrambled
MiaPaCa or Panc1 cells (Fig. 3B). Quantitative real-time PCR
analysis further shows that along with PD2 mRNA, there is also a
decrease in CHD1 mRNA level in PD2 siRNA treated Panc1 cells,
indicating that hPaf1 regulates CHD1 expression both at the
transcription and translational levels (Fig. S1A). Concurrently,
overexpression of PD2 in HPAF/CD18 pancreatic cancer cells
also upregulates CHD1 expression (Fig. S1B). These results
indicate that hPaf1/PD2 regulates the expression of the chromatin
remodeling protein CHD1, suggesting its possible role in the
rearrangement of the chromatin structure during transcription
elongation in pancreatic cancer cells.
hPaf1/PD2 interacts with CHD1 in both the cytoplasm
and the nucleus of pancreatic cancer cells
Chromatin remodeling protein CHD1 is known to interact with
transcription elongation factors and localize to actively transcribed
genes [31]. In yeast, CHD1 functions during transcription
elongation through interactions with elongation factors, Spt4-
Spt5 and Spt16-Pob3. Interestingly, CHD1 is also found to
interact with the Rtf1 subunit of the yeast PAF complex that
associates with RNA Polymerase II and regulates transcription
elongation [31]. Although the Rtf1 is present in humans, it is not
as a part of the hPAF complex. Therefore, we tested the possibility
that the hPaf1/PD2 subunit of the human PAF complex interacts
with CHD1 using co-immunoprecipitation studies. Western blot
analysis of the co-immunoprecipitates shows that PD2 interacts
with CHD1 in both cytoplasm as well as nuclear extracts of
pancreatic cancer cells, Panc1 and MiaPaCa (Fig. 4). We further
analyzed the interaction between PD2 and CHD1 by co-
localization studies using confocal microscopy (Fig. 5A). The
CHD1 staining (red) was found to overlap with the PD2 staining
(green), both in cytoplasm as well as in the nucleus of pancreatic
cancer cells in corroboration with the biochemical data. These
results suggest that PD2 and CHD1 interact and further
participate in chromatin structure remodeling in pancreatic
cancer.
Nuclear transport of CHD1 is facilitated by hPaf1/PD2 in
PC cells
Yeast homologue of CHD1 is found to be localized in the
cytoplasm as well as in the nucleus of cells, indicating that it
shuttles between the two cellular compartments to carry out its
function in determination of chromatin architecture during
transcription elongation. Further studies have shown that CHD1
is excluded from chromosomes during mitosis and again
reassociates back with the chromatin of the re-forming nucleus
during telophase-cytokinesis [29]. Interestingly, recent studies
done in our lab have shown that hPaf1/PD2 expression is
regulated in a cell-cycle dependent manner in pancreatic cancer
cells [32]. More so, the studies suggested that hPaf1/PD2 is
hPaf1 in Chromatin Remodeling of Pancreatic Cancer
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Figure 2. Expression of histone methyltransferase MLL1 in hPaf1/PD2 knockdown PC cells. (A) Panc1 and MiaPaCa pancreatic cancer
cells were transfected with scrambled and PD2 RNAi oligos and lysates were collected at 72 hours post transfection. Western Blot analysis using
specific antibodies shows a decrease in MLL1 histone methyltransferase protein expression in knockdown cells compared to scrambled cells. b-actin
served as a loading control. Quantification data of the western blot is provided below the corresponding immunoblot results for respective cell lines.
The error bars indicated represent standard error calculated from three independent experiments. * represents significant change (p,0.05) in protein
level between scrambled and PD2 knockdown cells. (B) Confocal microscope images illustrating PD2 and MLL1 localization in the nucleus of Panc1
cells. MLL1 colocalizes with PD2 in discrete regions within the nucleus (stained with DAPI) of Panc1 cells. The inset represents a magnified image of
the colocalization spots of PD2 and MLL1.
doi:10.1371/journal.pone.0026926.g002
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shuttled and accumulates in the cytoplasm during mitosis, whereas
it appears to concentrate within the condensed chromatin during
metaphase [29]. Given that hPaf1/PD2 interacts as well as
regulates the level of CHD1 in pancreatic cancer cells, and their
similarity in pattern of nuclear-cytoplasmic localization, we tested
whether PD2 helps in nuclear transport of CHD1 in pancreatic
cancer cells. To this end, we compared the CHD1 distribution in
the cytoplasm and nucleus of pancreatic cancer cells between
scrambled and PD2 knockdown pancreatic cancer cells using
confocal microscopy. The immunofluorescence studies clearly
revealed that PD2-specific siRNA treated cells had a reduced level
of hPaf1/PD2, which was primarily localized in the cytoplasm
compared to scrambled siRNA treated cells. Interestingly, along
with reduced PD2 expression, the PD2 knockdown cells showed a
decrease in the nuclear localization of CHD1 in both MiaPaCa
and Panc1 cells (Fig. 5A). Furthermore, Western blot analysis of
cytoplasmic and nuclear extracts from scrambled and PD2
knockdown MiaPaCa cells also showed a reduced CHD1 level
in the nuclear extracts of PD2 depleted cells (Fig. 5B). The
suggested role of PD2 in the CHD1 nuclear transport was
reconfirmed by a rescue experiment in which the PD2 knockdown
cells were further transfected with a pBABE-hygro vector
construct expressing full-length PD2. Significantly, re-expression
of PD2 in these cells showed a recovery of nuclear localization of
Figure 3. Downregulation of hPaf1/PD2 reduces the CHD1 protein level in PC cells. (A) Western blot analysis shows a decreased level of
the CHD1 protein in PC cells upon RNAi mediated hPaf1/PD2 inhibition. b-actin served as a loading control. The graph below each western blot figure
represents the corresponding quantification results for individual cell lines. (B) Immunofluorescence analysis showing a reduced hPaf1/PD2 level
(green) along with a corresponding reduction in CHD1 level (red) in PD2 siRNA treated PC cells compared to scrambled siRNA treated cells.
doi:10.1371/journal.pone.0026926.g003
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CHD1, similar to the scrambled si-RNA treated cells. PD2 and
CHD1 were also observed to have a similar distribution pattern in
cytoplasm and nuclear extract of other pancreatic cancer cells
(Fig. S2). Therefore, decreased nuclear accumulation of CHD1 in
PD2 knockdown cells indicates that hPaf1/PD2 facilitates the
nuclear import of CHD1 in pancreatic cancer cells to carry out its
function. This shuttling is hampered in the case of hPaf1/PD2
depleted cells.
hPaf1/PD2 knockdown affects nucleosomal remodeling
in PC cells
From recent studies it is becoming apparent that the nuclear
architecture and gene positioning contributes highly to gene
regulation [33]. The chromatin remodeling enzymes influence this
nuclear architecture restructuring by repositioning of the nucle-
osomes, thereby facilitating the progress of the RNA Polymerase II
and associated factors through transcription units. The hPAF
complex is known to be required for efficient transcriptional
elongation through chromatin. The yeast PAF complex was found
to mediate the increased efficiency of transcriptional elongation by
promoting nucleosomal destabilization and histone removal [20].
Our data shows that hPaf1/PD2 interacts with and regulates the
ATP-dependent chromatin remodeling enzyme, CHD1. There-
fore, in this regard, we tested whether knockdown of hPaf1/PD2
alters the nucleosomal positioning in pancreatic cancer cells. To
verify this, we transiently knocked down hPaf1/PD2 in pancreatic
cancer cells Panc1 and MiaPaCa using the siRNA approach and
performed micrococcal nuclease digestion to examine nucleosomal
occupancy. The variation in the pattern of the digested DNA
ladder is reflective of any change in the nucleosomal occupancy.
Comparison of the scrambled and PD2-specific siRNA treated
cells showed different micrococcal nuclease digestion patterns in
Panc1 (Fig. 6A) and MiaPaCa (Fig. 6B) cell lines. In both cell
types, each of the DNA ladder bands corresponds to either the
mononucleosome (147 bp) or polynucleosomes, in successively
increasing size. The ladder shows an increase in intensity with
increasing concentration of the micrococcal nuclease enzyme,
indicating a higher degree of digestion as the ratio of enzyme to
DNA ratio increases. Further, the intensity of the DNA ladder is
higher in the case of the PD2 knockdown cells compared to the
control cells. The densitometric analysis (Fig. 6A,B right panel)
shows the difference (marked in red asterix) in intensity of the
shortest band corresponding to the mononucleosome between
scrambled and knockdown cells. This indicates that the inter-
nucleosomal DNA is more accessible for MNase digestion in the
case of the knockdown cells. This is representative of the global
change in the nucleosomal positioning and hence does not reflect
the chromatin remodeling that could account for a change in any
particular gene expression. Both the pancreatic cancer cells, Panc1
and MiaPaCa, show a similar variation between control and PD2
knockdown cells. However, the change is more prominent in the
case of Panc1 cells which have higher PD2 levels because of the
amplification of the 19q13.2 locus. The above observations suggest
that PD2 has a direct bearing on the regulatory role of CHD1 in
chromatin remodeling, probably by regulating its nuclear import.
Discussion
Altered gene expression due to changes in the compact
chromatin structure and posttranslational histone modifications
has often been considered as a significant contributing factor for
tumor development [34]. Progression of pancreatic cancer, which
has a very poor prognosis and less than a 5% survival rate of five
years, is found to be associated with a host of changes in gene
expression. Here, we document that inhibition of hPaf1/PD2, a
subunit of the human RNA Polymerase II associated complex
which is known to be overexpressed in pancreatic cancer, and
leads to a reduction in the di and tri-methylation levels of histone
H3 lysine 4 residues in pancreatic cancer cells. A decrease in
hPaf1/PD2 level also led to a corresponding decrease in the level
Figure 4. Interaction of hPaf1/PD2 with CHD1 in pancreatic
cancer cells. (A) Cytoplasmic and nuclear extract fractionation was
performed in Panc1 and MiaPaCa pancreatic cancer cells followed by
reciprocal co-immunoprecipitation of endogenous proteins in the cell
fractions. Western blot analysis shows that hPaf1/PD2 interacts with
CHD1 in both cytoplasmic and nuclear extracts of Panc1 and MiaPaCa
pancreatic cancer cells. Anti-PD2 immunoprecipitates from extracts of
Panc1 and MiaPaCa cells were immunoblotted with an anti-CHD1
antibody. Similarly, anti-CHD1 precipitates were blotted with anti-PD2
antibody. Rabbit IgG was used as a control.
doi:10.1371/journal.pone.0026926.g004
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of MLL1, a histone methyltransferase that regulates H3K4 residue
methylation [3]. Inhibition of hPaf1/PD2 also led to a reduction in
the level of a chromatin remodeling enzyme CHD1 that
specifically binds H3K4Me2/3 and prevents its nuclear import.
Furthermore, hPaf1/PD2 knocked down pancreatic cancer cells
show an altered pattern of micrococcal nuclease digestion
compared to the control cells, indicating that PD2 might play an
important role in chromatin structure rearrangement through
CHD1 in pancreatic cancer.
We found that a siRNA mediated reduction of hPaf1/PD2 level
could decrease the level of di- and tri-methylation of histone H3 at
lysine 4 residue, although the change in monomethylation was
insignificant in pancreatic cancer cells. However, monomethyla-
tion is considered more as a steady state condition, whereas di and
Figure 5. hPaf1/PD2 assists in CHD1 nuclear import in pancreatic cancer cells. (A) Panc1 and MiaPaCa cells were transfected with
scrambled and PD2 RNAi oligos and 48 hours post transfection immunofluorescence analysis was carried out. Confocal images show that there is
decreased localization of CHD1 in the nucleus (blue, stained with DAPI) of PD2 KD pancreatic cancer cells (middle panel) compared to the scrambled
cells (top panel). Cells were further retransfected with pBABE-hygro PD2 construct for ectopic expression of PD2, 72 hours post intital transfection.
Confocal images illustrate addition of exogenous PD2 reshuttles CHD1 back to the nucleus (bottom panel). The inset represents PD2 and CHD1
localization in the nucleus (stained with DAPI). (B) Western blot analysis shows the distribution of CHD1 level in cytoplasmic and nuclear extracts of
PD2 knockdown vs. scrambled Panc1 and MiaPaCa cells.
doi:10.1371/journal.pone.0026926.g005
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tri-methylation of H3 tails on K4 (K4Me3) at the 59 end of the
transcribed region is a signature motif of highly expressed genes
and is known to enhance transcriptional elongation. Reduction in
hPaf1/PD2 level also led to a decrease in the level of the MLL1
protein, a mammalian homologue of the yeast Set1 histone
methyltransferase. Our studies also show that PD2 colocalizes with
MLL1 in pancreatic cancer cells. Interestingly, earlier studies
suggest that the yeast PAF complex is required for recruitment of
the COMPASS methyltransferase to RNA Polymerase II and
subunits of this complex interact physically [4]. Further, a recent
publication showed that only the hPaf1/PD2 subunit of the
human PAF complex interacts with MLL1 [26]. Therefore, our
results suggest that hPaf1 may regulate the histone methylation
level in pancreatic cancer cells by regulating the expression of
HMTs like MLL1, thereby linking transcriptional elongation to
chromatin modification. Given that pancreatic cancer is associated
with changes in gene expression, these changes in histone
methylation marks might contribute to pancreatic cancer
development and progression. Our current observations are
corroborated by studies done with the yeast PAF complexes,
Figure 6. Micrococcal nuclease digestion altered in hPaf1/PD2 knockdown pancreatic cancer cells. The micrococcal nuclease digestion
pattern of nuclei isolated from scrambled and PD2 kd Panc1 (A) and MiaPaCa cells (B). Nuclei were digested with increasing concentrations of
micrococcal nuclease enzyme (0.80 and 100 units) for 5 and 10 mins followed by DNA extraction using phenol-chloroform method. Five mg of DNA
was then separated in 1.5% agarose gel. The figures on the right hand side represent densitometry analysis of the DNA banding pattern and the
asterix in red shows difference between scrambled and knockdown cells.
doi:10.1371/journal.pone.0026926.g006
hPaf1 in Chromatin Remodeling of Pancreatic Cancer
PLoS ONE | www.plosone.org 10 October 2011 | Volume 6 | Issue 10 | e26926
which also play similar roles in transcriptional elongation and
regulation of mRNA stability as compared to the human
homologue. Studies show that the yPAF complex regulates post-
translation histone modifications such as methylation and
ubiquitynation. Therefore, it can be speculated that overexpres-
sion of hPaf1/PD2 in pancreatic cancer might lead to enhanced
histone methylation and upregulation of gene expression indis-
criminately. Interestingly, a recent study revealed that MLL1
histone methyltransferase is required for promoter methylation of
MDR1 (multi drug resistance gene), a member of the ATP-binding
cassette (ABC) transporter family that confers tumor drug
resistance by actively effluxing a number of antitumor agents
[35]. As evident from the studies done by Milne et al. and Muntean
et al., PAF1 complex is required for the recruitment of the MLL1
complex at the HOX loci and subsequent transformation [26,27].
Hence, it might be postulated that the human PAF complex
regulates methylation at histone 3 lysine 4 residues through MLL1
and might control gene expression of key proteins involved in
tumor initiation, development, progression or resistance to
antitumor therapy.
CHD1 is a protein belonging to the family of ATPase
dependent chromatin remodelers which specifically bind to di
and tri-methylated histone H3 at lysine 4 residue [6]. In this study,
we found that along with histone methylation, a reduction in
hPaf1/PD2 level also decreased the cellular level of CHD1
protein. CHD1 is localized both in the cytoplasm and the nucleus
of cells. Interestingly, PD2 knockdown pancreatic cancer cells
seemed to have reduced nuclear localization of CHD1 compared
to the scrambled cells, suggesting that the process of CHD1
nuclear shuttling is hampered due to hPaf1 knockdown. Earlier
studies have shown that nuclear-cytoplasmic localization of both
PD2 and CHD1 are cell-cycle dependent [29,32]. There is a
spatial-temporal correlation between the distribution of PD2 and
CHD1 in cells. CHD1 is absent from chromosomes during mitosis
and reassociates back with the nucleus during cytokinesis.
Strikingly, hPaf1 is also degraded during mitosis whereas it drives
cell-cycle progression in the G1, S and G2 phase by regulating
cyclin B1, D1 and E1 transcription initiation. The earlier studies
and the current results indicate that PD2 is perhaps involved in
facilitating the nuclear import of CHD1 to the nucleus, wherein it
helps in remodeling of the chromatin structure. Moreover, the
secondary structure of hPaf1/PD2 consists of a RCC1 (Regulator
of chromatin condensation) domain [19] which is homologous to
the RCC1 domain present in RanGTPase, a protein involved in
nuclear transport [36]. The potential involvement of the PD2
RCC1 domain in nuclear transport of CHD1 needs further
investigation. In this regard, a recent perspective on the stem cell
property of self renewal and pluripotency emphasizes that CHD1
is essential for open chromatin and pluripotency of embryonic
stem cells, and for somatic cell reprogramming to the pluripotent
state [37]. Interestingly, a recent study from our lab demonstrates
that the Paf1 subunit interacts with Oct3/4 and is also required for
the maintenance of mouse embryonic stem cell self renewal and
pluripotency [22]. Our results also show that PD2 interacts with
CHD1 both in cytoplasm as well as in the nucleus of pancreatic
cancer cells. It has been proposed that this interaction might be
important in stabilization of the binding of CHD1 to methylated
histones as well as in facilitation of its nuclear-cytoplasmic
shuttling. Overall, these studies strongly suggest a concerted
function between Paf1 and CHD1 proteins in regulating gene
expression, thereby affecting the process of cell cycle progression,
differentiation or tumor development.
Chromatin assembly may occur by an active histone
deposition mechanism in which CHD1 function is involved in
the transfer of histones to DNA as well as the formation of
periodic arrays of nucleosomes [5]. Thus, molecular motor
proteins, such as CHD1, function not only in the remodeling of
existing nucleosomes but also in de novo nucleosome assembly
from DNA and histones. The chromatin is always in a dynamic
state during gene expression; the histones are constantly
displaced and reintroduced to facilitate transcription. These
processes are carried out by active chromatin remodeling
proteins like CHD1 by harnessing the ATP energy. From the
micrococcal nuclease digestion experiment, it was observed that
the PD2 knockdown cells show a more intense DNA laddering
compared to control cells, indicating an increased susceptibility
to enzyme digestion. Since PD2 regulates the active transcription
mark, H3K4 di and trimethylation, the knockdown of hPaf1/
PD2 should lead to a decreased transcription. Apparently, the
micrococcal nuclease digestion pattern seems contradictory,
since the PD2 knockdown looks more accessible to digestion,
indicative of open chromatin and active transcription. However,
based on the dynamic model of nucleosomal assembly and
disassembly, it may be suggested that the hPaf1/PD2 knockdown
cells are in a more or less steady state due to decreased CHD1
levels and hence show a specific digestion pattern. On the other
Figure 7. Proposed model for regulation of histone methyla-
tion and chromatin remodeling by hPaf1/PD2. PD2 affects
methylation at H3K4 residue by regulating the histone methyltransfer-
ase MLL1. CHD1, a chromatin remodeling protein, that interacts with
PD2, then binds to these di-methylated and trimethylated H3K4
moieties. The expression as well as nuclear transport of the CHD1
protein is also regulated by hPaf1/PD2. Binding of CHD1 to the
modified histones finally leads to remodeling of the nucleosomal
structure resulting in a change in gene expression.
doi:10.1371/journal.pone.0026926.g007
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hand, the cancer cells with an overexpression of hPaf1/PD2 and
CHD1 have active transcriptional upregulation and, as a result,
chromatin rearrangement occurs, constantly making the chro-
matin template less accessible to nuclease digestion. However,
this study represents a global change in the nucleosomal
arrangement, although any change in chromosomal structure
leading to expression or repression of specific genes requires a
more in-depth analysis of the nucleosomal structure using
specific primers corresponding to the promoter region of target
genes for PD2 and CHD1. Therefore, our results suggest that the
hPaf1/PD2 subunit of the human PAF complex interacts with
the chromatin remodeling protein CHD1 in pancreatic cancer
cells, facilitating its nuclear import and thereby regulating its
function of nucleosomal remodeling (Fig. 7). Future studies may
address the genes whose expression is controlled by such an
interaction between hPaf1 and CHD1 and its significance in
pancreatic cancer development and progression. Overall, this
study emphasizes the role of key transcriptional regulators, like
the hPAF complex, in epigenetic changes and subsequent
variation of the chromosomal architecture, thereby determining
the state of gene expression critical to the process of
tumorogenesis.
Supporting Information
Figure S1 Quantitative Real-time PCR analysis of PD2
and CHD1 mRNA expression in hPaf1 knockdown vs
scrambled Panc1 cells. (A) Quantitative real-time PCR
analysis for mRNA expression of PD2 and CHD1 was done
using the following primers- CHD1 FP 59-TGAGC-
CATTTCTGTTACGCCGAGT-39, CHD1 RP 59-TGAGG-
TACTGCCCTTGGAACCTTT-39. Results show reduced level
of PD2 mRNA in Panc1 cells transfected with PD2 siRNA as
compared to scrambled siRNA treated cells. CHD1 mRNA level
also shows a corresponding decrease in expression in PD2
knockdown cells compared to control cells. The mRNA
expression level was determined after normalization with b-actin
mRNA expression. (B) Western blot analysis of PD2 and CHD1
in PD2 overexpressed HPAF/CD18 pancreatic cancer cells.
hPaf1/PD2 was ectopically overexpressed in HPAF/CD18
pancreatic cancer cells having low endogenous level of PD2 by
transfection with pBABE.hygro vector containing full-length PD2
construct. Western blot analysis shows that along with increase in
PD2 expression, CHD1 protein level as well as the histone H3
lysine 4 tri-methylation mark is also increased in the PD2
overexpressing HPAF/CD18 cells compared to vector transfected
cells. b-actin is used as the loading control.
(TIF)
Figure S2 Cytoplasmic and nuclear distribution of PD2
and CHD1 in different pancreatic cancer cell lines.
Immunoblotting with cytoplasmic and nuclear extracts collected
from pancreatic cancer cell lines – Capan2, S2CP9 and BxPC3
show that there is a correlation between the distribution of PD2
and CHD1 in the cellular compartments. Capan2 has higher PD2
as well as CHD1 content in the cytoplasmic extract whereas
S2CP9 and BxPC3 have higher level of both PD2 and CHD1 in
the nuclear extract. PGK and PARP serve as the loading controls
for cytoplasmic and nuclear extracts respectively.
(TIF)
Figure S3 Downregulation of hPaf1/PD2 using different
pool of siRNA and its effect on PAF complex subunits,
H3K4 methylation, MLL1 and CHD1 level. Other than the
siRNA (Dharnacon) used for knockdown of PD2/hPaf1, we also
used a different pool of siRNAs, obtained from SantaCruz
Biotechnologies (sc-76034) to downregulate PD2 in Panc1 and
MiaPaCa pancreatic cancer cells. The effect of PD2 knockdown
using the new pool of siRNAs was investigated by analyzing the
protein levels of other PAF complex subunits, H3K4 methyl-
ation, histone methyltransferase MLL1 and chromatin remod-
eling protein CHD1 by western blotting. The bar diagram
represents quantification of the western blot figures. b-actin is
used as the loading control and for normalization of the
quantification data.
(TIF)
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